Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (formerly BCTG Acquisition Corp, ticker: BCTG) completed its business combination with Tango Therapeutics in October 2021, taking the clinical-stage biopharmaceutical company public on Nasdaq. The SPAC was sponsored by Boxer Capital, LLC, an affiliate of Tavistock Life Sciences, and conducted its initial public offering in 2020. Tango Therapeutics focuses on precision oncology, developing targeted cancer therapies by identifying and exploiting synthetic lethal vulnerabilities in tumor cells. The June 2022 8-K filing represents a post-combination current report filed by the surviving public entity under the original SPAC registrant. For comprehensive SPAC filing history, deal terms, and sponsor data on Tango Therapeutics and thousands of other transactions, sign up for full access at SpacDesk.